LAG3 and melanoma: The combination of PD-1 and CTLA-4 blockade has demonstrated higher response rates in advanced melanoma [23], while combination with LAG3 blockade are still carrying on clinical trials (NCT03250832, NCT02658981, NCT01968109, NCT03005782).